Alzheimer disease trials in Romania

In Romania 12 Also abroad 815

12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Where
Brasov, Bucharest, Bucuresti, Constanța, Jassi, Sibiu
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00
No phaseTaking people
InRAD Observational Study
Where
Brasov, Bucharest
Age
18 years and over
People
50,000 worldwide
Run by
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
See details and how to joinNCT07213700
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Where
Bucharest, Galati, Sibiu
Age
55 years and over
People
370 worldwide
Run by
Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Where
Bucharest, Sanpetru, Sibiu
Age
55 years and over
People
320 worldwide
Run by
Intra-Cellular Therapies, Inc.
See details and how to joinNCT06651567 · EU 2024-514680-26-00
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Bucharest, Bucuresti, Constanța, Craiova, Oradea, Sibiu
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
Bucharest, Jassi
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Bucharest, Constanța, Craiova, Oradea, Sibiu
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Brasov, Bucharest, Bucuresti, Constanța, Jassi, Sibiu
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Brasov, Bucharest, Constanta
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Where
Bragadiru, Bucharest, Caracal, Jassi
Age
55 years to 90 years
People
300 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00
Phase 2Taking people
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
Where
Bucharest, Galati, Sibiu
Age
18 years and over
People
216 worldwide
Run by
Intra-Cellular Therapies Inc.
See details and how to join2024-513035-25-00 · EU 2024-513035-25-00
Phase 2Enrolling by invitation
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Where
Bragadiru, Bucharest, Caracal
Age
55 years to 91 years
People
210 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00